[#item_full_content] Brains Bioceutical Corp. has announced plans to list on Nasdaq, in what would be the first US public-market debut for a UK-based cannabinoid pharma manufacturer since GW Pharmaceuticals was acquired by Jazz in 2021. The company, headquartered in Vancouver, British Columbia, operates one of the largest cannabinoid active pharmaceutical ingredient (API) manufacturing facilities in the 
Read More
Brains Bioceutical To List On NASDAQ Via SPAC At US$750m Valuation
ByPot Shop News
November 6, 2026